On May 15, 2022, Clay B. Siegall, Ph.D., notified the board of directors of Nurix Therapeutics, Inc. of his resignation as a Class II member of the Board and as a member of the Board's Compensation Committee and Development Advisory Committee, effective immediately.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.22 USD | +0.46% | -2.40% | +59.45% |
11/06 | Nurix Therapeutics Files Mixed Shelf Registration | MT |
11/06 | Certain Restricted Stock Units of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024. | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+59.45% | 958M | |
+16.60% | 124B | |
+17.07% | 109B | |
-7.24% | 23.84B | |
+1.98% | 22.42B | |
-14.29% | 17.5B | |
-6.56% | 16.61B | |
-37.63% | 16.43B | |
+1.59% | 13.4B | |
+23.61% | 11.47B |
- Stock Market
- Equities
- NRIX Stock
- News Nurix Therapeutics, Inc.
- Nurix Therapeutics, Inc. announces Resignation of Clay B. Siegall as Class II Member of the Board and as Member of the Board’s Compensation Committee and Development Advisory Committee